ALB and neoplasm: The functionalization of radiopharmaceuticals with albumin-binding entities (the p-iodophenyl entity, truncated Evans blue, etc.)to enhance the serum half-life and, therewith, increase the tumor uptake has been investigated extensively in recent years [9].